This article is more than 5 years old. Information may no longer be current.

ViiV offers additional funds to pediatric HIV program

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ViiV Healthcare is providing more than $2.5 million in additional funds for the Collaborative Initiative for Paediatric HIV Education and Research program, or CIPHER, according to a press release from the International AIDS Society. The funding will be used to research and develop new ways to prevent HIV infections in children living in resource-limited settings.

“We are absolutely delighted, as the founding partner of such an innovative and successful initiative as CIPHER, to see the commitment and program expand based on the success of the initial 2-year program,” Dominique Limet, CEO of ViiV Healthcare, said in the release. “Pediatric HIV is one of our key priorities as part of our overall commitment to people living with HIV, and therefore we are proud to renew our support to CIPHER and the [International AIDS Society] for the next 2 years.”

According to the International AIDS Society (IAS), only 34% of eligible children receive HIV treatment — approximately half the rate of adults. In 2012, 39% of HIV-exposed infants were tested for the infection during the first 2 months of life, when the risk for death is highest. The priority of the CIPHER program is to reduce the pediatric treatment gap.

CIPHER also is currently advancing three other initiatives, including a grant program for young investigators to research topics related to pediatric HIV in resource-limited settings; an international collaboration of pediatric cohorts consisting of approximately 280,000 children and adolescents that will be used study the duration of first-line treatment and adolescent epidemiology and transition to adult care; and the launch of a new pediatric research database.

“These investments are fundamental in helping us address the treatment and prevention gaps among children,” Owen Ryan, executive director of IAS, said in a press release. “We are incredibly proud of our partnership with ViiV, without whom this work would not be possible.”